Therapy-related acute myelogenous leukemia and myelodysplastic syndrome
- First Online:
- Cite this article as:
- Borthakur, G. & Estey, E.E. Curr Oncol Rep (2007) 9: 373. doi:10.1007/s11912-007-0050-z
- 98 Views
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome (t-AML/MDS) are increasing in prevalence with aging of the population and improved survival of patients treated with chemotherapy or radiotherapy for other malignancies. Research focused on the pathogenesis of t-AML/MDS will provide insight into the pathogenesis of de novo AML/MDS. Participation in clinical trials should be encouraged for this patient population because results with available treatment options are clearly suboptimal.